Boson Ventures

🌟 Excited to share the success of our 2024 Australia-China BioInnovation Roundtable held in Melbourne last week! This milestone event brought together leading minds in biotechnology innovation and cross-border collaboration. Key discussions centered around three major themes: * Current landscape and opportunities in biotech * Supply chain integration and cross-border cooperation * Future investment outlook We were fortunate to have insightful research presentations from A/Prof Marina Zhang from Australia-China Relations Institute, University of Technology Sydney and Thom D. from Macquarie University, along with Dirk van der Kley from the National Security College who co-moderated the discussion. Their findings highlighted the evolving innovation ecosystems in both countries. Our Healthcare Investment Lead, Xiang Chen, shared valuable investment experience and provided an inspiring outlook for Australia-China biotech investment prospects. In-depth discussions highlighted the current state of innovation ecosystems between Australia and China, identifying key challenges and potential solutions. Participants stressed the importance of enhancing innovation frameworks and developing entrepreneurial ecosystems, with a focus on commercialising research outcomes. It was noted that Chinese biotech companies are proactively seeking opportunities in overseas markets. Australia can be pivotal in early-stage R&D. We will be organising key messages and insights from this roundtable in a white paper. Stay tuned for more updates on this important dialogue! Heartfelt appreciation to our supporting organizations: Australia China Business Council (ACBC) Australia China Alumni Association (ACAA) Australian Chinese Association of Scientists and Entrepreneurs (ACASE) Special thanks to Tom Parker 裴仁杰, National CEO of ACBC, for his invaluable support and coordination in making this event possible. We are also grateful to Helen Dai from Australian Trade and Investment Commission (Austrade) and Toby Graham from Global Victoria. And a special shout-out to Shuyun Zhang for her excellent event coordination. Looking ahead to 2025, we're committed to deepening Australia-China tech innovation cooperation, expanding beyond biotech into climatech, smart manufacturing, and new materials. Let's continue building bridges for innovation! 🌉 #Innovation #Biotech #AustraliaChina #Collaboration #bosonventures #FutureOfHealthcare Shuyun Zhang Xiang Chen Helena L. Curt Shi 侍海 Tom Parker 裴仁杰 Amir Zalcenstein Rhenu Bhuller Michael Macrides Isaac Huang Justin Howden Aodong Mei Amanda Xiaoqing Mao, PhD Professor Greg Li, MD PhD Eldin Rostom Catherine Dai Libby Kruse Margareta S. Paul Jensz Samira Sadeghi, Ph.D Ismat Kabbara Danzi (Daisy) Song Sara Cheng Grace Li Dr. Wenjie Yang

🌟 Excited to share the success of our 2024 Australia-China BioInnovation Roundtable held in Melbourne last week! This milestone event brought together leading minds in biotechnology innovation and cross-border collaboration. Key discussions centered around three major themes: * Current landscape and opportunities in biotech * Supply chain integration and cross-border cooperation * Future investment outlook We were fortunate to have insightful research presentations from A/Prof Marina Zhang from Australia-China Relations Institute, University of Technology Sydney and Thom D. from Macquarie University, along with Dirk van der Kley from the National Security College who co-moderated the discussion. Their findings highlighted the evolving innovation ecosystems in both countries. Our Healthcare Investment Lead, Xiang Chen, shared valuable investment experience and provided an inspiring outlook for Australia-China biotech investment prospects. In-depth discussions highlighted the current state of innovation ecosystems between Australia and China, identifying key challenges and potential solutions. Participants stressed the importance of enhancing innovation frameworks and developing entrepreneurial ecosystems, with a focus on commercialising research outcomes. It was noted that Chinese biotech companies are proactively seeking opportunities in overseas markets. Australia can be pivotal in early-stage R&D. We will be organising key messages and insights from this roundtable in a white paper. Stay tuned for more updates on this important dialogue! Heartfelt appreciation to our supporting organizations: Australia China Business Council (ACBC) Australia China Alumni Association (ACAA) Australian Chinese Association of Scientists and Entrepreneurs (ACASE) Special thanks to Tom Parker 裴仁杰, National CEO of ACBC, for his invaluable support and coordination in making this event possible. We are also grateful to Helen Dai from Australian Trade and Investment Commission (Austrade) and Toby Graham from Global Victoria. And a special shout-out to Shuyun Zhang for her excellent event coordination. Looking ahead to 2025, we're committed to deepening Australia-China tech innovation cooperation, expanding beyond biotech into climatech, smart manufacturing, and new materials. Let's continue building bridges for innovation! 🌉 #Innovation #Biotech #AustraliaChina #Collaboration #bosonventures #FutureOfHealthcare Shuyun Zhang Xiang Chen Helena L. Curt Shi 侍海 Tom Parker 裴仁杰 Amir Zalcenstein Rhenu Bhuller Michael Macrides Isaac Huang Justin Howden Aodong Mei Amanda Xiaoqing Mao, PhD Professor Greg Li, MD PhD Eldin Rostom Catherine Dai Libby Kruse Margareta S. Paul Jensz Samira Sadeghi, Ph.D Ismat Kabbara Danzi (Daisy) Song Sara Cheng Grace Li Dr. Wenjie Yang

We are thrilled to announce that our portfolio company, Hello Clever, has secured 2nd place on the AFR Australian Fast Starter 100 list! As the only Australian institutional investor in their Seed Round, we are proud to support their journey and success. Our investment philosophy is rooted in #high_conviction and #non_consensus approaches, and Hello Clever’s remarkable achievement is a testament to the potential we saw in them from the start. Congratulations to the entire Hello Clever team on this outstanding accomplishment! https://lnkd.in/gQ6ZENMX Helena L. Xiang Chen Shuyun Zhang Caroline Tran Vy (Gavin) Nguyen #fast100 #australianstartups #highconviction #nonconsensus

🌏 How Chinese Biopharma is Reshaping Global Biotech – What This Means for Australia  The innovation landscape in biotechnology is shifting, amidst rise in geopolitical tensions and ever-increasing healthcare-related spending. In our upcoming event, we are excited to collaborate with Dr. Dirk van der Kley from The Australian National University's Crawford School of Public Policy to explore what Australia can learn from global trends in biotechnology innovation and competitiveness. In his recent article, Dirk draws upon data from key data points including publications, clinical trial activity, and US FDA approvals to underscore the rapid emergence and growth of China’s innovative biopharma sector. Historically, China’s biotechnology industry has focused on upstream ingredient manufacturing, generics production, contract manufacturing and contract research. However, homegrown Chinese drug developers moving quickly and investing in innovation to challenge industry incumbents and break into global markets, especially in US. For Australia, these developments underscore both the opportunities and challenges of positioning ourselves as a leader in biotech amidst global competition. Join us for a unique discussion with industry experts and leaders including Dirk as we navigate the future of Australian biotech through a global lens. 📅 December 4th 12-4PM AEDT 📍 Virtual & in-person (Melbourne) 🔗 RSVP: https://lu.ma/qblain9u Looking forward to connecting with you! Event Supporters: Australia China Business Council Australia China Alumni Association ACASE #Biotech #Innovation #Australia #Pharma #FutureOfBiotech

 Exploring Australia's Role in the Future of Biotech amid Global Shifts  Boson Ventures is excited to invite you to our upcoming event, where we’ll explore how Australia can navigate the evolving landscape of biotechnology in the face of global geopolitical shifts. Australia-China Relations Institute, University of Technology Sydney' Associate Professor Marina Zhang recent article (link in comments) underscores how biotechnology is emerging as a new frontier in the U.S.-China decoupling, carrying major implications for global healthcare innovation. For Australia, this shift presents unique challenges and tremendous opportunities. This event will feature experts and thought leaders, including Dr. Zhang to discuss: ✅ Navigating the complexities of international trade regulations in the biotech sector ✅ Building resilient and adaptive supply chains for biotech materials and products ✅ Fostering innovation through strategic research collaborations across borders ✅ Strategic opportunities for Australian stakeholders in biotech Don’t miss this chance to engage in vital discussions about Australia’s biotech future and how we can drive innovation forward. December 4th 12-4PM AEDT Virtual & in person (Melbourne) RSVP here: https://lu.ma/qblain9u Looking forward to seeing you there and many thanks to our supporters: Australia China Business Council, Australia China Alumni Association, ACASE #Biotech #Innovation #Australia #USChinaRelations #Biotech

Did you also call us "Boston"(with a "t")⁉️ Our co-founder and GP Can (Alan) C. shared his personal journey and why we chose Boson (without a "t") as the name. 🌟 At Boson Ventures, we believe that our name embodies our commitment to deep tech innovation and the passion that drives our mission. Inspired by science ⚛️ and a dedication to nurturing startups 🚀, we are excited to share how our experiences shape our approach to empowering the next generation of groundbreaking technologies. Shuyun Zhang Helena L. #deeptech #innovation #science #founder #entreprenuer #personaljourney

Our GP, Can (Alan) C., presents a Chinese deep tech company weekly to assist Australian deep tech investors and founders in bridging the knowledge gap with their Chinese counterparts, as Chinese deep tech firms gain competitiveness in the global market.

We were honoured to attend the InnovationAus 2024 Awards for Excellence Gala Dinner last night in Sydney. It was an incredible evening celebrating Australia’s brightest innovators and their contributions to shaping the future across various sectors. The event highlighted groundbreaking advancements in areas such as AI, MedTech, energy, and manufacturing, showcasing the talent and vision driving our country forward. We are proud to be part of this innovative ecosystem and look forward to collaborating with the brilliant minds we connected with during the event. #innovationAus #Innovation #Excellence #AustralianTech #Collaboration Shuyun Zhang Helena L.

Last month, the U.S. House of Representatives passed the BIOSECURE Act, seeking to halt federal contracts with 5 life sciences companies: Wuxi AppTec, WuXi Biologics, BGI Group, MGI and Complete Genomics. China-based CROs and CDMOs play a pivotal role in the global biopharma industry and the Chinese domestic biotech ecosystem has evolved quickly in recent years, narrowing the innovation gap with Western leaders. In a rapidly evolving global landscape, how can Australia position itself to drive forward progress in bioinnovation and build a thriving biotech industry? We welcome interested leaders in industry, policy and academia to participate in a close-door discussion to share experiences, speak to challenges and identify opportunities to move forward on: - Fostering biotech talent through cross-border educational programs - Attracting venture capital and government investment for startups - Navigating complex trade regulations - Building resilient supply chains - Driving innovation through research collaborations We are excited to facilitate this event with leading scholars Marina Zhang (University of Technology Sydney) and Dirk van der Kley (The Australian National University) and with the support of organisations including Australia China Business Council, ACASE and Australia China Alumni Association. Express your interest to join the event via the link: https://lu.ma/qblain9u Places will be limited for in person and virtual attendees to ensure robust and fruitful discourse to capture diverse perspectives. Can (Alan) C. Helena L. Shuyun Zhang Danzi (Daisy) Song Sara Cheng Grace Li Aodong Mei Michael Macrides Joanna Chua (Ng)

We understand your unique business challenges. At Hello Clever, we believe there’s no one-size-fits-all approach when it comes to payments. We take the time to understand your business needs—whether it's cash flow issues or managing fraud—and deliver solutions that fit your specific challenges 🛠️ James Deans, our Partnerships & Growth Manager, has been working closely with our merchants and partners, helping them discover the unique benefits of Hello Clever’s products. James has been driving education and engagement, ensuring that our solutions empower businesses to grow and thrive. Learn how we’ve helped businesses like BatteryMate achieve a 35% conversion rate and how launtel improved payment flexibility for its customers. We're here to solve your problems, not just offer generic solutions. Reach out to James if you would like to discuss a potential partnership. Over the coming weeks, we'll be sharing a series of videos featuring James as he shares his insights on Hello Clever from a partnerships perspective. Stay tuned to gain valuable perspectives on how we’re helping businesses unlock growth opportunities! #HelloClever #Fintech #BusinessGrowth #TailoredSolutions #PaymentSolutions #BusinessSuccess #RealTimePayments